Zanganeh Mahkam
Co-Chief Executive Officer
Zanganeh Mahkam has filed 4 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Jun 12, 2026.
On the most recent filing, Zanganeh Mahkam is listed as Co-Chief Executive Officer at Summit Therapeutics Inc. Inside the rolling window, Zanganeh Mahkam reported 3 open-market purchases totaling $51.9M in SMMT and no open-market sales. The largest disclosed transaction in the window is a purchase of 3,810,000 SMMT shares on Jun 12, 2026, worth $50.0M.
Companies traded
Other insiders at SMMT
Insider Buying
$51.9M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Zanganeh Mahkam made?
Zanganeh Mahkam has filed 4 SEC Form 4 filings (7 transaction rows) across 1 company since 2025.
Which companies does Zanganeh Mahkam trade?
Zanganeh Mahkam has filed SEC Form 4 disclosures for 1 company, including SMMT.
When was Zanganeh Mahkam's most recent SEC Form 4 filing?
Zanganeh Mahkam's most recent SEC Form 4 filing on Tracefour is dated Jun 12, 2026.
What is Zanganeh Mahkam's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Zanganeh Mahkam is listed as Co-Chief Executive Officer.
What is Zanganeh Mahkam's total buy and sell value in the current window?
Inside the rolling retention window, Zanganeh Mahkam bought $51.9M and sold $0 based on SEC Form 4 filings.
What was Zanganeh Mahkam's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 3,810,000 SMMT shares on 2026-06-12, worth $50.0M, per SEC Form 4 filings.